In an interview with an Indian CFO, Shantanu Kumar Singh, Taj Pharma Group,
Mr. Singh commented, "A generic medicine treatment is now available within many of the major therapeutic classes and this is often the 'gold standard' option for specific diseases. Opportunities exist to recommend schedules that encourage initiation of treatment with these 'gold standard' generic medicines. This is a positive sign which should increase the uptake of these drugs and potentially generate long-term savings through the use of a safe and effective therapy at an affordable price. "
Singh also mentions, 'In 2011, 7% of revenues from the generics medicine industry were spent on research and development alone. Furthermore, sector investments in manufacturing and development facilities have created a solid base of employment (150,000 direct employees in the EU2) yielding societal benefits that go beyond the realms of healthcare. The potential benefits of the generics medicine industry will not be maximised if the focus is on the lowest price alone. There is a need to increase the volume of generic medicines penetration in the EU market and optimise such key areas as competition with in-patent medicines, co-payment policies, time to market, and ready supply'.
What do you think about the rising costs of health care in Europe?
The provision of an effective and efficient healthcare system in any country is a complex equation balancing appropriate levels of patient care with resources available. Within this lies the need for infrastructures to support both primary and secondary care as well as associated services such as social welfare. Making direct comparisons of costs and best practices across EU member states is difficult; inherent political differences give rise to highly variable systems. No one country is the same. However, one element that is common to all and often the focus of attention is the cost of medicines. Although medicines generally constitute only around 10% of a country's total healthcare budget (with generic medicines only comprising between 1-2%) they are a prime target for cost savings - despite being arguably the most cost-effective part of the healthcare solution. However, even here, the lack of coherent policies and variations in pricing and reimbursement systems, sociodemographics and the management of healthcare within each EU member state make comparisons difficult. What works in one country may be totally inappropriate in another. One thing is certain, the ageing population and changes in lifestyle automatically bring an increased demand for
healthcare and consequent escalation of costs. Pharmaceutical expenditure has been growing at comparable rates across all the major Western markets, with the developing markets exhibiting greater growth due to expanding access to medicines. Prolonged life expectancy in diseases previously associated with high mortality is also extending the use of longer-term chronic therapy treatments, further increasing the burden on healthcare providers. It is a fundamental principle in medicine that pharmaceuticals can delay or even prevent the need for costly hospitalisation in some patients. Therapies to improve quality of life in patients with terminal diseases are also playing a growing role in the physicians' armamentarium. Against this background, it is possible to draw a correlation between life expectancy and pharmaceutical consumption.
Pharmaceuticals undeniably play an essential role in improving and maintaining health, but managing and controlling cost remains a major challenge for society, including governments and payers. Although the percentage of GDP spent on healthcare is fairly consistent in the major EU countries, the absolute amounts available are straining to deliver the desired levels of healthcare.
You're announcing strong first half results today. What's driven that performance?
Shantanu Kumar Singh, CFO (Taj Pharma Group) comments, 'I have to say I'm very, very happy, we're extremely pleased by the results that we announced today'. We're looking at revenues up by 22.6%, we're looking at our operating profits up by 40%, gross margins are almost 50%, fantastic cash flow growth by 74%, and we have a fantastic net debt to equity ratio of 18%. So we're very, very happy with these numbers. I've always said that this is a very well diversified business, and we have three main engines that continuously feed this growth. So this year for the first half, the US Generic business did extremely, extremely well, so we're very happy with that. That has been fantastic growth. Our Injectable business for the first half was very good also, we're very happy with that. And the Brand business, as we had previously said, would this year be split almost evenly between the first half and second half. So the Brand business was stable and we are looking at very good growth in the Brand business for the second half of the year. So overall, all three engines have been performing quite well, and the diversity and diversification has come in and worked again to give us these fantastic results....
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Taj Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The interview given by Shantanu Kumar Singh CFO should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
About TF1 TV channel France
TF1 is a national French TV channel, controlled by TF1 Group, whose major share-holder is Bouygues. TF1's average market share of 24% makes it the most popular domestic network. Flagship shows include Star Academy (Endemol's international competitor to the X Factor franchise), CSI and House, M.D. TF1 originally stood for T?l?vision Fran?aise 1 (French Television 1). Since its privatisation in 1987, the abbreviation is no longer expanded, so as to avoid confusion with the government-owned channel France T?l?visions. The channel is part of the TF1 Group of mass media companies, which also includes the news channel LCI and Eurosport, the largest European sports network. Together with France T?l?visions, TF1 co-managed the international French news channel France 24 but has since sold its share. TF1 is a supporter of the Hybrid Broadcast Broadband TV (HbbTV) initiative (a consortium of broadcasting and Internet industry companies including SES, OpenTV and Institut f?r Rundfunktechnik) that is promoting and establishing an open European standard for hybrid set-top boxes for the reception of broadcast TV and broadband multimedia applications with a single user interface.
Taj Pharmaceuticals Group
Taj Pharmaceuticals Limited is known as a pharmaceuticals manufacturing company found and based in India. The company manufacturer's pharmaceuticals formulations and API for India and other countries. The company was established in 1995 as an enterprise and in 2004 became a public limited company. As per Mumbai pharmaxil and Chemixil association the company manufacturers and exports to countries like Iran, Iraq and Asia Pacific. In recent EU-Indonesia Business Dialogue (EIBD) conference Taj Pharma Group was listed amongst top 10 pharmaceutical companies in EU by 2008 sales. The Group sales 16,234 ($M) making the company 12 ranked in EU by 2008 sales. Founded as a company for finished formulation marketing and Export and then entered Api and Agro business in 2004 and 2007 respectively.Taj Pharmaceuticals Limited announced the purchase of Mulberry chemicals (MulChem) wholly-owned US subsidiary from REVIB, Administration (DEA) as a narcotic raw material manufacturer. The founder of Taj Pharmaceuticals, Dr. R. K. Singh, is known as entrepreneur who was convinced that the future belonged to branded pharmaceutical products way back in 1995. Mr Singh is among the first to recognize that the industrial manufacture of standardized medicines would be a major advance in the fight against disease. Dr. R. K. Singh attached great importance to product information as the link between the pharmaceutical manufacturer and doctors, pharmacists and patients. Shortly after the foundation of the company, affiliates were opened in Mauritius, Malaysia, Dubai, Moscow, England, France, the US, Great Britain and Russia.
Source: http://www.indiahealthandwellness.com/2012/02/tf1-survey-european-markets-dependence.html
susan lucci jim caviezel arturo gatti arturo gatti stoma stoma money ball
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.